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Background: A Mendelian transmission produces phenotypic and genetic relatedness between family members,
giving family-based analytical methods an important role in genetic epidemiological studies—from heritability
estimations to genetic association analyses. With the advance in genotyping technologies, whole-genome
sequence data can be utilized for genetic epidemiological studies, and family-based samples may become more
useful for detecting de novo mutations. However, genetic analyses employing family-based samples usually suffer
from the complexity of the computational/statistical algorithms, and certain types of family designs, such as
incorporating data from extended families, have rarely been used.
Results: We present a Workbench for Integrated Superfast Association studies for Related Data (WISARD)
programmed in C/C++. WISARD enables the fast and a comprehensive analysis of SNP-chip and next-generation
sequencing data on extended families, with applications from designing genetic studies to summarizing analysis
results. In addition, WISARD can automatically be run in a fully multithreaded manner, and the integration of R
software for visualization makes it more accessible to non-experts.
Conclusions: Comparison with existing toolsets showed that WISARD is computationally suitable for integrated
analysis of related subjects, and demonstrated that WISARD outperforms existing toolsets. WISARD has also been
successfully utilized to analyze the large-scale massive sequencing dataset of chronic obstructive pulmonary disease
data (COPD), and we identified multiple genes associated with COPD, which demonstrates its practical value.
Keywords: Family-based design, Genome-wide association analyses, Next generation sequencing, Multi-threaded
analyses, Related samplesBackground
Family-based samples have different properties from
population-based samples because of Mendelian trans-
mission, and this well-known feature has allowed family-
based designs to play a key role in genetic epidemiology
from the very beginning of genetic analysis. For instance,
phenotypic correlations between family members enable
the estimation of heritability via a linear mixed effects* Correspondence: tspark@stats.snu.ac.kr; won1@snu.ac.kr
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disease-causing loci using a few large families [2–5].
Recently, rare variants have been recognized as a main
source for the so-called missing heritability [6], and the
importance of family-based designs has been repeatedly
stressed for analyses with sequence data because of
genetic homogeneity between family members [7].
Furthermore, in the presence of population substruc-
ture, statistical methods for association analysis with
population-based samples are often similar to those for
family-based samples. The presence of population sub-
structure generates correlations between population-basedle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Fig. 1 Lists of tasks supported by WISARD. famUniq (Family-unique
variants), popUniq (P opulation-unique variants), fastEpi (Fast-epistasis
method), FQLS (Family QLS method), inbCoef (Inbreeding coefficients),
MFQLS (Multivariate FQLS)
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stantial for phenotypes with a large polygenic effect. For
instance, around 30% of the phenotypic variance of height
is captured by the genetic relationship matrix (GRM) [8]
and the linear mixed effects model can be used to take
into account the correlations between subjects. For quan-
titative phenotypes, a number of methods with high com-
putational efficiency have recently been introduced [9, 10],
and have been successfully applied to genome-wide asso-
ciation studies [11–13]. For dichotomous phenotypes, the
nonlinear models might be considered to be a reasonable
and appropriate approach. However, generalized linear
mixed effects models that use maximum likelihood for
estimation and approximations to avoid numerical
integration have a serious bias introduced by the approxi-
mation [14, 15]. In order to overcome this issue, score
statistics such as FBAT [16] and MQLS [17] have been
proposed as alternatives.
However, in spite of such improvement, there is no
integrated toolset for an analysis of large-scale family-
based samples, and statistical analysis has often suffered
from computational intensity. In this paper, we intro-
duce a Workbench for Integrated Superfast Analyses for
Related Data (WISARD), which is thoroughly optimized
for analysis in a multi-core system and has comprehen-
sive features for various analyses. Furthermore we
propose two novel methods for rare variant association
analysis with related samples, cFARVAT and famVT.
WISARD features three major functionalities: data man-
agement, quality control (QC), and association analysis.
WISARD provides various tasks for large-scale genetic
data management such as retrieval, conversion, split and
merging of datasets with various formats. For extended
families, the family-based imputation performed by
WISARD is useful for handling missing genotypes.
Second, genotype quality for each variant or each subject
can be evaluated using several statistics, and samples
and variants can be filtered based on quality scores.
Third, WISARD provides useful functions for associ-
ation analyses ranging from heritability estimations to
joint association analysis with multiple genotypes and
phenotypes. With the integration of R, WISARD enables
longitudinal data analysis, and the graphical
summarization of analysis results. A list of tasks sup-
ported by WISARD with family-based samples is shown
in Fig. 1.
To demonstrate the performance and practicality of
WISARD, we compared its performance with existing
toolsets by using genetic analysis workshop (GAW) 18
dataset, and statistical powers of two new methods for
rare variant association analysis were evaluated with
GAW17 dataset. Moreover, we also analyzed the Boston
Early Onset Chronic Obstructive Pulmonary Disease
(EOCOPD) dataset. We found that WISARDoutperforms existing toolsets. These results illustrate the
practical value of WISARD, and how it can strengthen
the analytical power of analysis of large-scale genetic
datasets for newcomers.
Implementation
Data management
WISARD has many functions related to data manage-
ment and can simply conduct retrieval, conversion, split-
ting and merging of a large-scale genetic data with
various formats. At the same time, we provide a simple
method to impute missing genotypes for typed variants
based on the familial relationship and calculate the ex-
pected genotypes for untyped subjects. For instance, if
the phenotypes of any untyped subjects in each family
are available, their genotypes can be imputed from their
relatives’ genotypes and then imputed genotypes can be
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functions for data managements are available, providing
enormous convenience for analysis. Furthermore 15 dif-
ferent file formats including variant call format (VCF)
can be easily converted to other file formats.
Quality control
Many functions for quality control and summarization
measures for both chip-based and sequencing-based
data are implemented. The quality control process can
be accomplished by many QC measures such as Hardy-
Weinberg equilibrium, minor allele frequency (MAF),
minor allele count (MAC), genotype missing rate, or
Mendelian error rate. In addition, many elementary
statistics for genetic datasets are also provided, including
Ts/Tv ratio, inbreeding coefficient and Fixation index.
Statistical analyses
WISARD can perform various association analyses in
multi-threaded manner. Statistical analyses implemented
in WISARD are listed in Table 1. WISARD can conduct
variant-level, gene-gene interaction, and gene-level tests
for both dichotomous and quantitative phenotypes.
Variant-level tests are usually used for association ana-
lysis with common variants and include the linear mixed
effects models for quantitative phenotypes [10] and
quasi-score tests for the dichotomous phenotype [17,
18]. Extended quasi-score tests for multiple phenotypes
and variants [19] are also implemented. For gene-geneTable 1 A list of association tests supported by WISARD
Variant types
Phenotype
Population-based
samples
Family-based samples,
or population-based
sample under
population substructure
Common
Binary Cochran-Armitage
Logistic regression
MDR [22]
TDT/SDT
(family-based only)
FQLS [44]
MFQLS [19]
MQLS [17]
Continuous Linear regression
Generalized
MDR [21]
Score test for linear
mixed model
GEMMA [10]
Rare
Binary CMC [45]
C-alpha [46]
KBAC [47]
SKAT [25]
SKAT-o [26]
Weighted-sum
test [48]
PEDCMC [27]
FARVAT [28]
mFARVAT [29]
FARVATx [30]
FB-SKAT [49]
rvTDT [50]
Continuous VT [24]
SKAT [25]
SKAT-o [26]
Q-test [51]
FARVAT [28]
cFARVAT-b /
cFARVAT-s /
cFARVAT-o
famVTinteraction, Boolean operation-based screening and test-
ing method [20], and multifactor dimensionality reduc-
tion methods [21, 22] are implemented for detecting
gene-gene interaction for independent subjects. In
addition, gene-level tests are often used for association
analysis with rare variants, and cover the combined and
multivariate collapsing test [23], variable threshold (VT)
method [24], and SKAT [25, 26], etc. In particular, most
of gene-level tests were limited to population-based
samples, and few approaches available for family-based
samples. PEDCMC [27], FARVAT [28], mFARVAT [29],
and FARVATx [30] are implemented in WISARD.
Furthermore, we provided new statistics, family-based
VT and family-based SKAT-o. Both are denoted by famVT
and cFARVAT-o in the remainder of this report. Family-
based burden and SKAT tests are denoted by cFARVAT-b
and cFARVAT-s. Detailed methods for those statistics are
provided in Additional file 1: Supplementary text.
Implementation
Distinctive feature of WISARD is an implementation of
functions for various statistical analyses such as linear
mixed effects model, quasi-likelihood approaches. How-
ever in spite of their statistical efficiency, parameter esti-
mation for linear mixed models and quasi-likelihood
approaches require many matrix related operation and it
is computationally very intensive. For instance, genome-
wide analyses often take more than a few months if sam-
ple size is a few thousands or more. Therefore multiple
software have been proposed to improve the computa-
tional complexity, and they utilized existing C/C++ li-
braries for matrix calculation such as EIGEN (http://
eigen.tuxfamily.org), and LAPACK (http://www.netlib.
org/lapack/). We developed our own C/C++ library for
matrix operations, and its computational efficiency
improves the computational time of WISARD. Imple-
mented C/C++ library has four different property,
compared to existing software; (1) row-wise matrix
access, (2) efficient use of symmetric matrix, (3) applica-
tion of Single-Instruction-Multiple-Data (SIMD), and (4)
sweep-operator. Detailed explanation is provided in
Additional file 1: Supplementary text.
Methods
Comparison of computational efficiency with GAW18
datasets
Computational efficiency was compared with GAW18
simulation dataset. GAW18 dataset has sequences of
odd numbered chromosomes for 464 subjects from 20
extended Mexican-American families, and a set of 200
replicated phenotypes were generated from real geno-
types. We considered continuous phenotype Q1. We
considered variants whose P values for HWE are less
than 10− 8, call rates are larger than 0.95 and Mendelian
Lee et al. BMC Medical Genomics 2018, 11(Suppl 2):39 Page 36 of 116error rates are less than 0.01. Subjects whose call rates
are less than 0.95 and Mendelian error rates are larger
than 0.01 were excluded. For performance comparison,
we considered variant-level analyses, gene-level analyses
and calculating GRM and identity-by-state (IBS) matrix.
For gene-level tests, we consider only rare variants
whose MAFs are less than 0.05. For GRM, IBS calcula-
tion and variant-level tests, we considered variants
whose MAFs are larger than 0.05. Multithreaded ana-
lyses with 2, 4 and 8 threads were also performed
(Additional file 1: Figure S1).
Recently many toolsets for analysis of large-scale se-
quencing dataset have been proposed, but most of them
can analyze only population-based samples. Very few
toolsets are available for family-based samples. For in-
stance, PLINK2 is an extension of the well-known tool-
set for analyses of population-based genetic dataset,
PLINK [31], but it is limited to data management and
quality controls. In order to demonstrate capability and
computational efficiency of WISARD, we consider the
recently developed toolsets for large-scale genetic data-
set analyses with family-based samples: GEMMA for
variant-level analyses [10] and Rvtests for gene-level
tests [32]. Rvtests was the most recently developed tool-
set and provides most comprehensive features for rare
variant association analyses. famSKAT [33] is also
considered for family-based rare variant association
analyses. For common variant association analyses,
GEMMA is one of the fastest toolset for linear mixed
effects model [10]. FREGAT provides an integrated R
framework for gene-level tests with family-based
samples. However despite FREGAT provides extensive
family-based analyses, it was excluded from the compu-
tational performance comparison, since FREGAT is an R
package and it runs comparably very slow.
All analyses were performed using a dedicated computing
node with two Intel Xeon processors and 128GiB of RAM,
and all software were independently executed to minimize
any perturbation for checking net performance. Each ana-
lysis was executed five times and their mean execution
times were compared with their variation.
Evaluations of new methods with GAW17 datasets
GAW 17 dataset were used to evaluate validity of pro-
posed gene-level tests (famVT and cFARVAT-o).
GAW17 is an artificial dataset that consists of a single
set of odd-numbered chromosomes generated from 697
subjects from 1000 Genomes Projects, and 200 repli-
cates of simulated phenotypes. We considered continu-
ous phenotype Q1. We considered variants whose P
values for HWE are less than 10− 8, call rates are larger
than 0.95 and Mendelian error rates are less than 0.01.
Subjects whose call rates are less than 0.95 were
excluded. Each variant was annotated with UCSCGenome Browser (genome version GRCh37), and rare
variants of which MAFs were less than 0.05 were used
to make a gene set file for gene-level tests. To adjust the
population substructure, variance-covariance matrix was
parameterized with GRM, and variants whose MAFs are
larger than 0.05, were used to get GRM matrix.
For evaluation of proposed methods, we estimated the
empirical type 1 errors and statistical powers. The
empirical type-1 errors were estimated by calculating
proportions of non-causal genes whose P values are less
than several significance levels with 1000 permuted phe-
notypes. The statistical powers were estimated by using
six predefined causal genes of 200 simulated phenotypes
in GAW17. Their estimated statistical powers were com-
pared with existing toolsets for family-based analyses:
MONSTER [34], famSKAT [33], and famBT, FFBSKAT,
MLR in FREGAT [35], as well as the methods for ana-
lysis of independent samples: SKAT and CMC.
Boston Early-onset COPD study dataset
We applied the proposed rare variant association statis-
tics to whole-exome sequencing data from the Boston
Early-onset COPD (EOCOPD) Study [36]. Whole exome
sequencing was performed at the University of Washing-
ton Center for Mendelian Genomics. We utilized the
same strategies for quality control of sequencing data by
Wang, et al. (2016). Quality control included Mendelian
error rates (< 1%), Hardy-Weinberg equilibrium
(P > 10− 8), and average sequencing depth (> 12).
Relatedness of subjects was evaluated by comparing the
kinship coefficient matrix (KCM) and GRM.
Heterozygous/homozygous genotype ratio, Mendelian
errors, the proportion of variants in dbSNP, and
proportion of nonsynonymous variants were used to
identify outliers. After subjects with missing phenotypes
or covariates were filtered out and 254 subjects from 49
families were analyzed.
For gene-level rare variant association analyses, we as-
sumed that variants with MAFs less than 0.05 were rare.
We then annotated the rare variants to genes with
UCSC Genome Browser (genome version GRCh37). We
considered genes with at least two rare variants, and 4
or more MAC, and thus 8126 genes that consist of
88,373 rare variants were analyzed. We considered five
COPD-related phenotypes: forced expiratory volume in
1 s. prebronchodilator (FEVPRE); forced vital capacity
postbronchodilator (FVCPST); forced expiratory flow
25–75% prebronchodilator (DPRF2575); FEVPRE di-
vided by FVCPRE (RATIO); DPRF2575 divided by
FVCPRE (F2575RAT). Sex, age, height, and pack-years
of cigarette smoking were utilized as covariates. For
variance-covariance matrix, we applied both KCM and
GRM according to the status of population substructure.
Population substructure was not detected and KCM was
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Bonferroni correction was applied for multiple testing
problem.Results
Comparison of available functions
Table 2 shows summary of available functions in
WISARD and its functionalities were compared with
other toolsets. As was shown in Table 2, PLINK2 [37]
lacks association tests for related subjects. GCTA [38]
supports single file format and does not support any as-
sociation analyses. Numbers of filtering functions for
WISARD, PLINK2, GCTA and Rvtests are 70, 54, 10
and 17, respectively, and WISARD provides the largest
filtering functions. Furthermore WISARD supports
regular expression and conditional statement for filtering
variants and subjects. Those are helpful for in-depth
analysis of the dataset for various purposes. For gene-
level association analysis, WISARD supports six types of
gene mapping file format: refFlat format, two interval
formats and three direct mapping format while other
toolsets support only one or two formats. In addition,
WISARD has more functions for statistical analyses such
as X-chromosome gene-level association analysis with
the family-based dataset, FARVATx [30], and allows
multi-thread analyses except few analyses such as PCA
analysis and heritability with ‘--thread’ option.Comparison of computational efficiency with GAW18
datasets
Computational efficiency of WISARD was compared
with GAW18 dataset. Figure 2 shows that WISARD
consistently has superior performance than Rvtests and
GEMMA up to twice acceleration (Fig. 2). For variant-
level association analyses with linear mixed models,
WISARD was compared with GEMMA and was around
1.7 times faster (Fig. 2). Even though GEMMA has been
a well-optimized program coded in C/C++ with
high-performance matrix calculation library, our imple-
mentation achieved further computational improvement.
Performance of gene-level analyses with WISARD showed
even more differences.
Figure 2 also shows that WISARD outperforms Rvtests
in all tests we considered. Largest difference of gene-
level analyses was observed for SKAT analyses, and com-
putation with WISARD is 205 times faster. For IBS and
GRM calculation, Rvtests use vcf2kinship, and it is used
for comparison. Figure 2 shows that WISARD is consist-
ently around 2.3 times faster than Rvtests for IBS calcu-
lation, and slightly better for GRM calculation. If two or
more threads are used, their differences become larger.
Last we compared results from GAW18 dataset by
WISARD and compared toolsets, and check whethertheir results are same. Additional file 1: Table S1 shows
their differences are almost negligible.
Evaluations of new methods with GAW17 datasets
We estimated type-1 errors and statistical powers of the
proposed methods with GAW17 dataset and they were
compared with other methods. Table 3 shows that all
methods except MONSTER preserve the nominal type-1
error rates. MONSTER consistently shows inflated type-
1 error rates, and it is partially due to the population
substructures because it cannot utilize IBS or GRM.
Next, we calculated the empirical statistical powers with
200 replicates. Figure 3a and b show the empirical power
estimates without and with PC adjustments, and adjust-
ment with PC scores generally improved the statistical
power of all methods. PC scores were estimated with
EIGENSTRAT approach [39]. cFARVATo always exhibits
good performance, and famVT becomes modest at the
smaller significance levels. MONSTER has good statis-
tical powers, but does not control the nominal signifi-
cance level correctly. SKAT and three methods from
FREGAT (famFLM, FFBSKAT and MLR) have lower
statistical powers than other methods for all scenarios.
SKAT showed lowest performance and it may be attrib-
utable to misspecified variance-covariance matrix.
Therefore we can conclude that the proposed methods
have good performance, compared to existing toolsets.
Real data analysis of EOCOPD dataset
Analyses results for 5 phenotypes of EOCOPD dataset
are summarized in Fig. 4. Figure 4a and b indicate
quantile-quantile (QQ) plots for all phenotypes with sta-
tistics implemented in WISARD and compared toolset
respectively. In Fig. 4a, cFARVAT-o and famVT are
newly proposed methods, and pedCMC was proposed
by Zhu and Xiong [27]. Figure 4 shows that results are
quite similar among methods. Rare variant analyses of
FVCPST with cFARVAT showed moderate inflation, and
results from other phenotypes seem to be statistically
valid. Statistics implemented by compared toolsets are
generally inflated except MONSTER. MONSTER
showed the similar pattern as the proposed methods,
but results for DPOF2575 tend to be liberal. In contrast,
famSKAT method consistently has inflated P values for
all phenotypes, which leads to a large number of false
positives. Four methods implemented in FREGAT
(famBT, famFLM, FFBSKAT, and MLR) consistently
showed inflated pattern except for RATIO as well.
Table 4 shows the number of significant genes at the
Bonferroni-adjusted 0.05 significance level by the num-
ber of analyzed genes. It should be noted that P values
from famSKAT, famFLM, FREGAT and MLR, tend to be
liberal and it is why they have many significant results.
WISARD was a unique toolset that preserves the
Table 2 Comparison of available functions for existing toolsets
Category
Functions
WISARD PLINK2 GCTA FREGAT Rvtests
Input format
PED O O X X X
Binary PED O O O O X
VCF O O X O O
Binary VCF O O X X X
Dosage O O O X X
Others O O X O X
Random dataset O O X X X
Recode dataset
PED O O X X X
Binary PED O O O X X
VCF O O X X X
Binary VCF O O X X X
Others O O O X X
Data manipulation
# of variant filters 38 27 8 0 11
# of gene filters 4 0 0 0 2
# of subject filters 28 27 2 0 4
Family-specific filters O X X X X
VCF-specific filters O X X X O
Data merge O O X X X
Covariate filters O O X X X
Data split O O X X X
Distance matrix
# of input formats 4 1 1 0 1
# of output formats 4 1 1 0 1
# of producible distances 7 2 1 0 4
Data summary
Variant summary O O X X X
Gene summary functions O X X O X
Variant-level analysis of unrelated samples
binary phenotypes O O O X O
continuous phenotypes O O O X O
multivariate phenotypes O O O X O
Gene-level analysis of unrelated samples
binary phenotypes O O X O O
continuous phenotypes O O X O O
multivariate phenotypes O X X X O
X-chromosome O X X X X
Variant-level analysis of related samples
binary phenotypes O X O X O
continuous phenotypes O X O X O
multivariate phenotypes O X O X O
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Table 2 Comparison of available functions for existing toolsets (Continued)
Category
Functions
WISARD PLINK2 GCTA FREGAT Rvtests
Gene-level analysis of related samples
binary phenotypes O X X O O
continuous phenotypes O X X O O
multivariate phenotypes O X X X O
Others features
Variant-level meta-analysis O O X X O
Gene-level meta-analysis O X X X O
R connectivity O O X O X
Multi-thread analyses O O O O O
Programming Language C/C++ C/C++ C/C++ R C/C++
# of supported platforms 5 3 1 3 1
Fig. 2 Comparisons of computational time. Computational times were compared with GAW18 simulation data. In each plot, bars indicate
execution time in seconds, and their amount can be obtained from left y-axis. Confidence intervals were calculated from five runs. Right y-axis is
for red lines and they indicate relative ratios between WISARD and other existing toolset. Relative ratios which are larger than 1 indicate that
WISARD is computationally faster, and horizontal blue dashed line indicates 1 for relative ratios. Regression and Fisher’s exact test from WISARD
were compared with results from R. In the plots for GRM and IBS, dashed, dotted and dash-dotted red lines indicate relative ratios when 2, 4 and
8 threads of WISARD are used, compared to Rvtests with the same number of threads
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Table 3 Estimated type-1 error rates
α WISARD
cFARVAT-s cFARVAT-b cFARVAT-o famVT
0.1 0.093 (±0.024) 0.096 (±0.023) 0.093 (±0.022) 0.081 (±0.02)
0.05 0.047 (±0.016) 0.048 (±0.017) 0.048 (±0.016) 0.043 (±0.016)
0.01 0.01 (±0.006) 0.01 (±0.007) 0.011 (±0.007) 0.012 (±0.008)
α famSKAT MONSTER FREGAT
famBT famFLM FFBSKAT MLR
0.1 0.097 (±0.029) 0.128 (±0.021) 0.1 (±0.03) 0.104 (±0.032) 0.101 (±0.032) 0.104 (±0.032)
0.05 0.05 (±0.02) 0.072 (±0.019) 0.048 (±0.02) 0.051 (±0.023) 0.058 (±0.022) 0.053 (±0.023)
0.01 0.011 (±0.008) 0.022 (±0.006) 0.01 (±0.008) 0.016 (±0.014) 0.012 (±0.009) 0.016 (±0.013)
Empirical type-1 error rates at the several significance levels and their standard errors which is in parenthesis were estimated with GAW17 simulation data
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significant genes for all phenotypes. P values from
MONSTER are generally stable, but it was not able to
discover any significant gene except DPOF2575. Thus
we focused on genes identified by WISARD due to its
unacceptably high Q-Q trend of famSKAT, famFLM,
famSKAT and FFBSKAT, and SKAT. Additional file 1:
Table S2 shows summary for significant genes by
WISARD. According to our results, for DPOF2575 and
F2575RAT, our methods except cFARVATb identified
FGD5. In addition, association of B3GNTL1 andFig. 3 Power comparison of the proposed methods (cFARVAT-b, cFARVAT-o
with GAW17 dataset. X and Y axes indicate significance level for power evalua
results without and with PC adjustment, respectivelySLC2A7 for FVCPST were also identified from famVT
and 3 cFARVAT, respectively. FGD5 belongs to RhoGEF
family, and activates expression of CDC42. For the
other genes of RhoGEF family and CDC42, previous
investigation revealed their role as a druggable target
of COPD [40, 41], as well as their relationship of
COPD [42]. SLC2A7 (GLUT7) is a member of
glucose transporters (GLUT) family, which shows a
substantial relationship with COPD [43]. PRRG2 and
CENPQ are newly discovered genes, and further
investigation for both are necessary.and famVT) and compared methods. Statistical powers were estimated
tion and statistical power estimates, respectively. Figures (a) and (b) show
Fig. 4 QQ plots of results from WISARD and compared methods for phenotypes of EOCOPD dataset. Red and black straight lines indicate y = x,
and its confidence intervals respectively. a QQ plots of results from WISARD methods. b QQ plots of results from compared methods
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WISARD enables automatic visualization of the results
of statistical analysis, using commands in the R program.
Furthermore, the web-based WISARD can annotate each
marker and provide information about the disease
susceptibility loci reported in the GWAS catalogue, the
Human Gene Mutation Database (HGMD) and Online
Mendelian inheritance in Man (OMIM). Figure 5 depicts
the result from web-based WISARD applied to
EOCOPD data.
Discussion
Over the last decade, thousands of GWAS have been
conducted to identify disease susceptibility loci, and
many causal variants for phenotypes have been identi-
fied. However, missing heritability remains a challenge,and genetic analysis with next-generation sequencing
technology has been expected to provide some clues.
Even though various genetic analyses have been con-
ducted to address these unsolved questions, most of
them have not yet been answered, and development of
an analysis toolset that enables thorough and compre-
hensive analysis is in demand.
In this paper, we present a comprehensive workbench,
WISARD, for the analysis of large-scale genetic data with
family-based samples. WISARD provides various func-
tions for quality control, data management and extensive
statistical analyses for family-based samples, and it is
also useful for population-based samples in the presence
of a population substructure. The quality of each variant
and subject can be evaluated with familial relationship,
and statistical analyses can be conducted by allowing for
Table 4 Number of significant genes at the Bonferroni-adjusted 0.05 significance level
Phenotype WISARD
PedCMC famVT SKAT cFARVAT-s cFARVAT-b cFARVAT-o
DPOF2575 4 2 0 1 0 1
F2575RAT 0 1 1 1 0 1
FEVPRE 1 0 1 0 0 0
FVCPST 4 1 2 3 2 3
RATIO 1 0 0 0 0 0
Phenotype famSKAT MONSTER FREGAT
famBT famFLM FFBSKAT MLR
DPOF2575 5 1 1 11 5 11
F2575RAT 0 0 0 4 0 4
FEVPRE 2 0 0 11 3 11
FVCPST 9 0 0 34 9 34
RATIO 0 0 0 0 0 0
Rare variant association analyses of DPOF2575, F2575RAT, FEVPRE, FVCPST and RATIO were conducted with EOCOPD data. Upper and lower table display results
from WISARD and other toolsets, respectively. Bolded numbers represent the number of identified genes from newly proposed methods
Fig. 5 An example of plots and summary tables generated from Web-WISARD
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WISARD takes account of correlations between subjects,
and our analysis with simulated data showed that
WISARD outperforms similar existing toolsets with re-
spect to computational time, which implies that the
genome-wide analysis is achievable in a relatively short
time. Furthermore, we proposed two novel methods for
rare variant association analyses with related samples,
and found that it achieves reasonable statistical power
and preserves the nominal significance levels. Moreover,
application of the proposed methods to EOCOPD data-
set successfully identified significant genes, and thus
these results illustrate its practical value.
Recent improvements in genotyping technology enable
the identification of rare variants for common diseases,
and large families have been expected to play a key role
for rare variant association analysis. However, in spite of
the various advantages of family-based designs, their
statistical analysis has often been complicated because of
relatedness between family members. WISARD provides
comprehensive functions for various genetic analyses
with large families, and it enables researchers’ efficient
large-scale genetic analysis.Additional file
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of significant genes from statistics implemented in WISARD. famVT and
cFARVAT-o are newly proposedmethods. (Chr = chromosome, # var. = number
of variants in the gene, MAC = sum of minor allele count). Figure S1.
Multithreading efficiency of WISARD analyses with varying number of threads.
Acceleration folds of the nine analyses with (A) 2 threads, (B) 4 threads, and
(C) 8 threads were obtained. X and Y axes respectively represent
chromosomes of GAW18 dataset and acceleration folds compared to the
single-thread execution time. Solid lines represent observed acceleration
folds of nine different analyses, and red dashed line represents upper limit
of speedup with given number of threads. Regression and Fisher tests by
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